652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II

TeclistAMY EMN40 A Phase 2 trial of teclistamab in patients with previously treated light chain AL amyloidosis

Determinants of renal survival in patients treated for monoclonal gammopathy of renal significance

Impact of slim CRAB criteria on diagnostic practices among patients with MGUS in the veteran health administration

Single cell landscape of clonal plasma cells in t 11 14 primary light chain amyloidosis reveals molecular insights into venetoclax response

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra low pass whole genome sequencing

Fat pad biopsy versus target organ biopsy in systemic AL amyloidosis detection

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara VCD

Bayesian machine learning medical history and predictive models for early diagnosis of systemic light chain amyloidosis

Association between monoclonal gammopathy of undetermined significance and cardiovascular disease risk among individuals with type 2 diabetes A Taiwan nationwide Study

Renal amyloidosis related mortality trends and disparities A retrospective nationwide analysis using the CDC wonder database

Clinical anatomic and histologic determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis A cohort study of 560 patients

Real world safety and efficacy of BCMA bispecific antibodies in relapsed light chain amyloidosis